来源：新浪证券-红岸工作室 9月30日，白云山涨0.24%，成交额2.19亿元。两融数据显示，当日白云山获融资买入额2235.80万元， 融资偿还4527.56万元，融资净买入-2291.76万元。截至9月30日，白云山融资融券余额合计10.15亿元。 融资方面，白云山当日融资买入2235.80万元。当前融资余额10.13亿元，占流通市值的2.82%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，白云山9月30日融券偿还2.12万股，融券卖出500.00股，按当日收盘价计算，卖出金额1.28万 元；融券余量7.80万股，融券余额199.29万元，超过近一年60%分位水平，处于较高位。 资料显示，广州白云山医药集团股份有限公司位于广东省广州市荔湾区沙面北街45号,香港金钟道89号 力宝中心第2座20楼2005室，成立日期1997年9月1日，上市日期2001年2月6日，公司主营业务涉及中西 成药、化学原料药、天然药物、生物医药、化学原料药中间体的研究开发、制造与销售;西药、中药和 医疗器械的批发、零售和进出口业务;大健康产品的研发、生产与销售;及医疗服务、健康管理、养生养 老等健康产业投资等。主营业务 ...

分红方面，白云山A股上市后累计派现109.06亿元。近三年，累计派现43.59亿元。 机构持仓方面，截止2025年6月30日，白云山十大流通股东中，香港中央结算有限公司位居第五大流通 股东，持股4044.81万股，相比上期增加936.01万股。华泰柏瑞沪深300ETF（510300）位居第七大流通 股东，持股1263.59万股，相比上期增加107.81万股。易方达沪深300医药ETF（512010）位居第八大流 通股东，持股1152.43万股，相比上期减少92.48万股。易方达沪深300ETF（510310）位居第九大流通股 东，持股893.66万股，为新进股东。 融券方面，白云山9月26日融券偿还7100.00股，融券卖出2.00万股，按当日收盘价计算，卖出金额50.76 万元；融券余量10.45万股，融券余额265.22万元，超过近一年90%分位水平，处于高位。 资料显示，广州白云山医药集团股份有限公司位于广东省广州市荔湾区沙面北街45号,香港金钟道89号 力宝中心第2座20楼2005室，成立日期1997年9月1日，上市日期2001年2月6日，公司主营业务涉及中西 成药、化学原料药、天然药物、生物医药、化 ...

Core Viewpoint - Baiyunshan Pharmaceutical Group has shown mixed financial performance with slight revenue growth but a decline in net profit, alongside significant trading activity in its stock [2][3]. Financial Performance - For the first half of 2025, Baiyunshan achieved operating revenue of 41.835 billion yuan, representing a year-on-year increase of 1.93% [2]. - The net profit attributable to shareholders was 2.516 billion yuan, reflecting a year-on-year decrease of 1.31% [2]. Stock Trading Activity - On September 5, Baiyunshan's stock price increased by 0.34%, with a trading volume of 237 million yuan [1]. - The financing buy-in amount for Baiyunshan on the same day was 28.51 million yuan, while the financing repayment was 51.72 million yuan, resulting in a net financing outflow of 23.22 million yuan [1]. - As of September 5, the total financing and securities lending balance for Baiyunshan was 974 million yuan, with the financing balance accounting for 2.61% of the circulating market value [1]. Shareholder Information - As of June 30, 2025, Baiyunshan had 85,500 shareholders, a decrease of 8.54% from the previous period [2]. - The top ten circulating shareholders included Hong Kong Central Clearing Limited, which increased its holdings by 9.36 million shares [3].

Group 1 - Baiyunshan's stock price increased by 0.45% on September 2, with a trading volume of 392 million yuan [1] - The financing buy-in amount for Baiyunshan on the same day was 52.78 million yuan, while the financing repayment was 75.43 million yuan, resulting in a net financing outflow of 22.65 million yuan [1] - As of September 2, the total financing and securities lending balance for Baiyunshan was 1 billion yuan, with the financing balance accounting for 2.65% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - Baiyunshan's main business includes the research, development, manufacturing, and sales of traditional Chinese and Western medicines, chemical raw materials, and health products, with major revenue sources being large commercial (69.32%), health (16.79%), and traditional medicine (12.53%) [2] - For the first half of 2025, Baiyunshan reported a revenue of 41.835 billion yuan, a year-on-year increase of 1.93%, while the net profit attributable to shareholders was 2.516 billion yuan, a decrease of 1.31% year-on-year [2] Group 3 - Baiyunshan has distributed a total of 10.256 billion yuan in dividends since its A-share listing, with 3.708 billion yuan distributed in the last three years [3] - As of June 30, 2025, the top ten circulating shareholders of Baiyunshan included Hong Kong Central Clearing Limited and several ETFs, with notable changes in shareholding among these entities [3]

Group 1 - The core viewpoint of the news highlights the recent trading performance and financing activities of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, indicating a decline in stock price and significant financing activities [1] - On August 27, Baiyunshan's stock price fell by 2.03%, with a trading volume of 454 million yuan, and a net financing purchase of 802,100 yuan, reflecting high financing levels compared to the past year [1] - As of August 27, the total financing and securities lending balance for Baiyunshan reached 870 million yuan, with financing balance accounting for 2.29% of the circulating market value, indicating a high level of financing activity [1] Group 2 - Baiyunshan's main business includes the research, development, manufacturing, and sales of traditional Chinese and Western medicines, chemical raw materials, and health products, with major revenue contributions from large commercial operations (69.32%) and health-related products (16.79%) [2] - For the first half of 2025, Baiyunshan reported a revenue of 41.835 billion yuan, a year-on-year increase of 1.93%, while the net profit attributable to shareholders decreased by 1.31% to 2.516 billion yuan [2] - The company has distributed a total of 10.256 billion yuan in dividends since its A-share listing, with 3.708 billion yuan distributed in the last three years [3] Group 3 - As of June 30, 2025, Baiyunshan had 85,500 shareholders, a decrease of 8.54% from the previous period, with an average of 16,443 circulating shares per shareholder [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited increased its holdings by 9.3601 million shares, while the E Fund CSI 300 Medical ETF reduced its holdings by 924,800 shares [3] - The company continues to attract institutional investment, with new shareholders entering the market, indicating ongoing interest in Baiyunshan's stock [3]